ReviewAnnals of translational medicine2013
The fetal liver as cell source for the regenerative medicine of liver and pancreas.
Review in Annals of translational medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Immunogenicity of Fetal Liver-Derived Progenitor and Stem Cells: Expression of MHC Molecules.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Therapeutic Cell Repopulation of the Liver: From Fetal Rat Cells to Synthetic Human Tissues.Cells · 2023Review
- Adult Stem Cell Therapy as Regenerative Medicine for End-Stage Liver Disease.Advances in experimental medicine and biology · 2022Article
- Stem/progenitor cells in fetuses and newborns: overview of immunohistochemical markers.Cell regeneration (London, England) · 2021Review
- Simulated microgravity promotes the formation of tridimensional cultures and stimulates pluripotency and a glycolytic metabolism in human hepatic and biliary tree stem/progenitor cells.Scientific reports · 2019Article
- Applications of stem cells and bioprinting for potential treatment of diabetes.World journal of stem cells · 2019Review
- Dynamics of Telomere Length and Telomerase Activity in the Human Fetal Liver at 5-12 Weeks of Gestation.Stem cells international · 2018Article
- Cryopreservation protocol for human biliary tree stem/progenitors, hepatic and pancreatic precursors.Scientific reports · 2017Article
- Hyaluronan coating improves liver engraftment of transplanted human biliary tree stem/progenitor cells.Stem cell research & therapy · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients affected by liver diseases and diabetes mellitus are in need for sources of new cells to enable a better transition into clinic programs of cell therapy and regenerative medicine. In this setting, fetal liver is becoming the most promising and available source of cells. Fetal liver displays unique characteristics given the possibility to isolate cell populations with a wide spectrum of endodermal differentiation and, the co-existence of endodermal and mesenchymal-derived cells. Thus, the fetal liver is a unique and highly available cell source contemporarily candidate for the regenerative medicine of both liver and pancreas. The purpose of this review is to revise the recent literature on the different stem cells populations isolable from fetal liver and candidate to cell therapy of liver diseases and diabetes and to discuss advantages and limitation with respect to other cell sources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.